{"id":47358,"date":"2022-08-16T20:02:01","date_gmt":"2022-08-16T18:02:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/"},"modified":"2022-08-16T20:02:01","modified_gmt":"2022-08-16T18:02:01","slug":"crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/","title":{"rendered":"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator"},"content":{"rendered":"
\n

\nTechnology Driven Insights to Improve CRISPR Edit Outcomes\n<\/p>\n

SAN DIEGO–(BUSINESS WIRE)–#CRISPR<\/a>–On August 12, 2022, EvoNexus, California\u2019s leading non-profit tech incubator, selected CRISPR QC to become a portfolio company.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThe right environment and mentorship is critical to the success of any early stage company. As a returning alumnus of the EvoNexus program, I’m thrilled to be bringing CRISPR QC into their portfolio and know just how well they can boost the growth of the company<\/i>,” states Ross Bundy, President of CRISPR QC.\n<\/p>\n

\n\u201cSince 2010, EvoNexus portfolio companies have raised over $1.7B with 40 exits totaling over $2.1B,<\/i>\u201d states Rory Moore, Co-Founder & CEO, EvoNexus. “We are pleased to have CRISPR QC enter our incubation program and once again have the opportunity to work with Ross Bundy. CRISPR QC leverages technology developed at his previous company, Cardea Bio, an EvoNexus graduate.<\/i> Healthcare technology has always been a focus area of EvoNexus with over 40 startups launched in that sector.<\/i>\u201d\n<\/p>\n

\nCRISPR Cas9 Editing, the discoverers of which were recently awarded a Nobel Prize, has the potential to be defining technology of the 21st<\/sup> century. Demand for CRISPR\/Cas9 gene-editing has exploded because of its huge potential for curing genetic diseases and for improvements that help secure our food supply in the face of challenges like climate change and global conflict. However, CRISPR will not be able to scale to its full potential and minimize the potential harm without effective standardization and quality control.\n<\/p>\n

\nAt CRISPR QC, we leverage CRISPR-Chip\u2122, to provide unique and quantitative insight to CRISPR that provides the foundational knowledge and measurements required for this much-needed scalable standardization and quality control. CRISPR QC will become the standard by which gene editing therapies and other CRISPR applications are measured to ensure safety and efficacy.\n<\/p>\n

\nAs a part of the EvoNexus community, CRISPR QC will accelerate growth by tapping into EvoNexus\u2019s extensive network of investors, demonstrated entrepreneurs, and technology leaders who are all dedicated to EvoNexus portfolio companies\u2019 success.\n<\/p>\n

\nAbout <\/b>CRISPR QC<\/b>\n<\/p>\n

\nCRISPR QC is a biotechnology company empowering scientists using CRISPR to solve the world\u2019s great challenges by providing the key cornerstones of information and insight fundamental to realizing the full potential of CRISPR.\n<\/p>\n

\nTo learn more about CRISPR QC, visit www.crisprqc.com.<\/a>\n<\/p>\n

\nAbout EvoNexus<\/b>\n<\/p>\n

\nEvoNexus is a San Diego-based deep tech non-profit incubator with a portfolio of over 250 technology startups. EvoNexus enables entrepreneurs to turn their transformative ideas into fundable, commercially-viable companies. Over 400 venture capital funds have invested in EvoNexus companies. EvoNexus is supported by corporate partnerships. For more information, please visit evonexus.org<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nRoss Bundy, President
\n
CRISPR QC
\n
858-444-0037
\n
rbundy@crisprqc.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Technology Driven Insights to Improve CRISPR Edit Outcomes SAN DIEGO–(BUSINESS WIRE)–#CRISPR–On August 12, 2022, EvoNexus, California\u2019s leading non-profit tech incubator, selected CRISPR QC to become a portfolio company. \u201cThe right environment and mentorship is critical to the success of any early stage company. As a returning alumnus of the EvoNexus program, I’m thrilled to be … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47358","6":"format-standard","7":"category-industry"},"yoast_head":"\nCRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Technology Driven Insights to Improve CRISPR Edit Outcomes SAN DIEGO–(BUSINESS WIRE)–#CRISPR–On August 12, 2022, EvoNexus, California\u2019s leading non-profit tech incubator, selected CRISPR QC to become a portfolio company. \u201cThe right environment and mentorship is critical to the success of any early stage company. As a returning alumnus of the EvoNexus program, I’m thrilled to be ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-16T18:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220812005446\/en\/1425692\/21\/CRISPR_QC_Logo_RGB-02.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator\",\"datePublished\":\"2022-08-16T18:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/\"},\"wordCount\":448,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005446\\\/en\\\/1425692\\\/21\\\/CRISPR_QC_Logo_RGB-02.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/\",\"name\":\"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005446\\\/en\\\/1425692\\\/21\\\/CRISPR_QC_Logo_RGB-02.jpg\",\"datePublished\":\"2022-08-16T18:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005446\\\/en\\\/1425692\\\/21\\\/CRISPR_QC_Logo_RGB-02.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005446\\\/en\\\/1425692\\\/21\\\/CRISPR_QC_Logo_RGB-02.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/","og_locale":"en_US","og_type":"article","og_title":"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator - Pharma Trend","og_description":"Technology Driven Insights to Improve CRISPR Edit Outcomes SAN DIEGO–(BUSINESS WIRE)–#CRISPR–On August 12, 2022, EvoNexus, California\u2019s leading non-profit tech incubator, selected CRISPR QC to become a portfolio company. \u201cThe right environment and mentorship is critical to the success of any early stage company. As a returning alumnus of the EvoNexus program, I’m thrilled to be ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-16T18:02:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220812005446\/en\/1425692\/21\/CRISPR_QC_Logo_RGB-02.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator","datePublished":"2022-08-16T18:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/"},"wordCount":448,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220812005446\/en\/1425692\/21\/CRISPR_QC_Logo_RGB-02.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/","url":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/","name":"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220812005446\/en\/1425692\/21\/CRISPR_QC_Logo_RGB-02.jpg","datePublished":"2022-08-16T18:02:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220812005446\/en\/1425692\/21\/CRISPR_QC_Logo_RGB-02.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220812005446\/en\/1425692\/21\/CRISPR_QC_Logo_RGB-02.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/crispr-qc-accepted-into-evonexus-san-diegos-premier-startup-incubator\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"CRISPR QC Accepted into EvoNexus \u2013 San Diego\u2019s Premier Startup Incubator"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47358"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47358\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}